Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Halimu N Haliduola

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Computer Methods and Programs in Biomedicine|October 19, 2022
Missing data imputation using utility-based regression and sampling approachesHalimu N Haliduola, Frank Bretz, Ulrich Mansmann
Biometrical Journal. Biometrische Zeitschrift|March 10, 2022
Missing data imputation in clinical trials using recurrent neural network facilitated by clustering and oversamplingHalimu N Haliduola, Frank Bretz, Ulrich Mansmann
Immunotherapy Advances|January 25, 2024
<i>Ex vivo</i> comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira<sup>®</sup> or undergoing repeated switches between Humira<sup>®</sup> and AVT02Kathleen Richter, Halimu N Haliduola, Jana Schockaert, et al.
BMC Medical Research Methodology|October 8, 2022
Joint analysis of PK and immunogenicity outcomes using factorization model - a powerful approach for PK similarity studyHalimu N Haliduola, Fausto Berti, Heimo Stroissnig, et al.
Expert Opinion on Biological Therapy|July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisSteven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy|October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adultsChristopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 19, 2023
Assessing the Interchangeability of AVT02 and Humira<sup>®</sup> in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group StudySteven R Feldman, Richard Kay, Nataliya Reznichenko, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Expert Opinion on Investigational Drugs|February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Expert Opinion on Biological Therapy|October 7, 2022
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeNemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Computer Methods and Programs in Biomedicine|October 19, 2022
Missing data imputation using utility-based regression and sampling approachesHalimu N Haliduola, Frank Bretz, Ulrich Mansmann
Biometrical Journal. Biometrische Zeitschrift|March 10, 2022
Missing data imputation in clinical trials using recurrent neural network facilitated by clustering and oversamplingHalimu N Haliduola, Frank Bretz, Ulrich Mansmann
Immunotherapy Advances|January 25, 2024
<i>Ex vivo</i> comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira<sup>®</sup> or undergoing repeated switches between Humira<sup>®</sup> and AVT02Kathleen Richter, Halimu N Haliduola, Jana Schockaert, et al.
BMC Medical Research Methodology|October 8, 2022
Joint analysis of PK and immunogenicity outcomes using factorization model - a powerful approach for PK similarity studyHalimu N Haliduola, Fausto Berti, Heimo Stroissnig, et al.
Expert Opinion on Biological Therapy|July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisSteven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy|October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adultsChristopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 19, 2023
Assessing the Interchangeability of AVT02 and Humira<sup>®</sup> in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group StudySteven R Feldman, Richard Kay, Nataliya Reznichenko, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Expert Opinion on Investigational Drugs|February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Expert Opinion on Biological Therapy|October 7, 2022
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeNemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, et al.
Pageof 2